non-small cell lung cancer
Conditions
Interventions
High TyG group (>8.60) / Low TyG group (=8.60):None
Sponsors
Jinan Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old, gender not restricted; 2. Advanced non-small cell lung cancer (stage IIIb/IIIc or IV) confirmed by histological or cytological examination; 3. First-time treatment patient, having not received any systemic anti-tumor therapy (including chemotherapy, targeted therapy, immunotherapy, etc.) before; 4. Plan to receive monotherapy or combination therapy with immune checkpoint inhibitors (ICIs); 5. Available for providing pre-treatment fasting triglyceride (TG) and fasting blood glucose (FPG) test results for calculating the TyG index; 6. Has measurable lesions (in accordance with RECIST 1.1 criteria); 7. ECOG performance status score 0-1; 8. Good organ function, meeting the following laboratory test standards: 9. Complete blood count: Neutrophils >= 1.5×10^9/L, Platelets >= 100×10^9/L, Hemoglobin >= 90 g/L; 10. Liver and kidney function: ALT/AST <= 2.5× upper limit of normal (ULN), Total bilirubin <= 1.5×ULN, Creatinine <= 1.5×ULN; 11. Voluntary to sign the informed consent form and able to cooperate with follow-up and data collection.
Exclusion criteria
Exclusion criteria: 1. Exclude cases with a history of other malignant tumors (except for cured non-melanoma skin cancer, cervical carcinoma in situ, etc.); 2. Have active autoimmune diseases or have had immune-related adverse reactions requiring systemic treatment in the past; 3. Are currently using systemic glucocorticoids (> 10 mg/day prednisone equivalent dose) or other immunosuppressants; 4. Have severe metabolic diseases (such as uncontrolled diabetes, thyroid dysfunction, etc.) that affect the interpretation of the TyG index; 5. Have had severe cardiovascular diseases, liver or kidney failure, active infections, etc. and are not suitable for immunotherapy; 6. Are unable to obtain complete baseline or follow-up metabolic indicators (TG, FPG); 7. Pregnant or lactating women; 8. Other situations that the investigator deems not suitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Overall survival; | — |
Countries
China
Contacts
Public ContactSun meili
The Central Hospital Affiliated to Shandong First Medical University
Outcome results
None listed